Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.Lee, T., Bian, Z., Zhao, B., Hogdal, L.J., Sensintaffar, J.L., Goodwin, C.M., Belmar, J., Shaw, S., Tarr, J.C., Veerasamy, N., Matulis, S.M., Koss, B., Fischer, M.A., Arnold, A.L., Camper, D.V., Browning, C.F., Rossanese, O.W., Budhraja, A., Opferman, J., Boise, L.H., Savona, M.R., Letai, A., Olejniczak, E.T., Fesik, S.W.
(2017) FEBS Lett. 591: 240-251
- PubMed: 27878989
- DOI: 10.1002/1873-3468.12497
- Primary Citation of Related Structures:
- Also Cited By: 5UJB
- PubMed Abstract:
Myeloid cell leukemia 1 (Mcl-1) is an antiapoptotic member of the Bcl-2 family of proteins that when overexpressed is associated with high tumor grade, poor survival, and resistance to chemotherapy. Mcl-1 is amplified in many human cancers, and knock ...
Myeloid cell leukemia 1 (Mcl-1) is an antiapoptotic member of the Bcl-2 family of proteins that when overexpressed is associated with high tumor grade, poor survival, and resistance to chemotherapy. Mcl-1 is amplified in many human cancers, and knockdown of Mcl-1 using RNAi can lead to apoptosis. Thus, Mcl-1 is a promising cancer target. Here, we describe the discovery of picomolar Mcl-1 inhibitors that cause caspase activation, mitochondrial depolarization, and selective growth inhibition. These compounds represent valuable tools to study the role of Mcl-1 in cancer and serve as useful starting points for the discovery of clinically useful Mcl-1 inhibitors.
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA.,Department of Adult Oncology, The Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Hematology and Medical Oncology and The Winship Cancer Institute, Emory University, Atlanta, GA, USA.,Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.,Vanderbilt University Medical Center, Nashville, TN, USA.